Overview

Safety And Tolerability Of Ziprasidone In Adolescents With Schizophrenia

Status:
Terminated
Trial end date:
2009-06-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to assess the safety and tolerability of ziprasidone during long-term open-label administration in adolescents (ages 13-17) with schizophrenia.
Phase:
Phase 3
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Ziprasidone
Criteria
Inclusion Criteria:

- Participation in double-blind treatment study A1281134, meeting specific criteria of
duration and safety

Exclusion Criteria:

- Imminent risk of suicide or homicide, as judged by the site investigator

- Serious adverse event related to study medication in study A1281134

- Significant prolongation of QT interval in study A1281134